The surge in volatility in April has alarmed many investors but according to Oppenheimer, it is the best time to look for investment opportunities. Here are 2 special observed stocks.
Volatility dominated stock markets throughout April, causing confusion and concern among investors. But for Oppenheimer analysts, this volatility is not a cause for alarm, but rather an opportunity. They identified 2 healthcare stocks that could generate returns of up to 150%, rating them as “strong buys”.
- Cboe volatility (VIX)
- Source: Tradingview
These stocks, with solid foundations and promising prospects, could represent interesting investment opportunities for those willing to tolerate a certain degree of risk. Oppenheimer therefore has an optimistic approach, seeing market fluctuations as an opportunity to make strategic investments.
Let’s see in detail what makes these actions so special and interesting.
1. Avalo Therapeutics (AVTX)
- AVTX daily graph
- Source: Tradingview
Avalo Therapeutics is a biopharmaceutical company that is making great strides in the field of autoimmune and inflammatory diseases. Its lead drug, AVTX-009, is an anti-IL-1β monoclonal antibody, ready for Phase 2 testing. This medication is intended to treat hidradenitis suppurativa, a painful inflammatory condition with few effective treatment options. Clinical trial data is expected in 2026, but the potential is already enormous.
The company also made a strategic move in March of this year, acquiring AlmataBio and with it the AVTX-009 drug candidate. This move gave Avalo the chance to further expand into the inflammatory disease space, with plans to test the drug in other indications. Additionally, Avalo raised money to support research, securing $185 million in a private placement.
Oppenheimer analysts are bullish on Avalo Therapeutics. With an “Outperform” (i.e., Buy) rating, they see AVTX-009’s potential and the company’s long-term vision as a reason to invest. The price target is $35, suggesting an upside of 150% over the next 12 months. With these predictions, Avalo Therapeutics is a stock worth watching.
2. AngioDynamics (ANGO)
- AngioDynamics daily graph
- Source: Tradingview
AngioDynamics is a leading company in medical technology, specializing in the production of devices for minimally invasive interventions. Founded in 1988, the company has built a solid reputation with innovative products such as AlphaVac, used in endovascular therapies, and NanoKnife, a device used for localized oncology treatments.
AngioDynamics recently released financial results for its third fiscal quarter 2024, showing an 8% increase in revenue compared to the prior year. However, the company reported a net loss of 16 cents per share. Despite this negative data, AngioDynamics has several growth opportunities ahead of it. The company is focusing on higher-margin MedTech products, such as Auryon, AngioVac/AlphaVac, and NanoKnife, and plans to expand into new global markets.
Oppenheimer has assigned AngioDynamics an “Outperform” rating, with a minimum target price of $12, which suggests a 100% upside over the next 12 months, and an average target between $14.5 and $15 (with an upside of 150%). Even though the company’s shares have fallen 21% this year, Oppenheimer sees a promising future thanks to its pipeline of innovative products and expansion into new markets.
With these two stocks, Avalo Therapeutics and AngioDynamics, Oppenheimer has identified significant growth opportunities in the healthcare sector. For investors willing to endure market volatility, these stocks could offer extraordinary returns over the next 12 months.
| DISCLAIMER The information and considerations in this article should not be used as the sole or primary basis for making investment decisions. The reader maintains full freedom in his own investment choices and full responsibility in making them, since he alone knows his risk propensity and his time horizon. The information contained in the article is provided for informational purposes only and its disclosure does not constitute and should not be considered an offer or solicitation to the public for savings. |
Original article published on Money.it Italy 2024-05-06 16:28:38. Original title: 2 azioni strong buy con target fino al 150% secondo Oppenheimer
